Stella Pharma Corporation · TSE:4888

Stella Pharma — Q2 FY2025/3 Earnings Presentation

40 slides from Stella Pharma's earnings presentation, November 2024

  1. Slide 1: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

    COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  2. Slide 2: BNCT mechanism: boron-10 and thermal neutrons

    熱中性子 7Li核 4μm 4He核（α粒子） 9μm 10B 1 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED. 1) 住友重機械工業株式会社ホームページhttps://www.shi.co.jp/industrial/jp/product/medical/bnct/neucure.html（2021年10月11日アクセス）

  3. Slide 3: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

    2 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  4. Slide 4: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

    3 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  5. Slide 5: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

          4 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  6. Slide 6: Income statement summary

    153 169 +15 169 - 455 438 △16 505 △66 (145) (136) (△9) (174) (△38) △301 △269 +32 △335 +66 △303 △267 +36 △338 +71 △305 △268 +37 △339 +71 5 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  7. Slide 7: Ordinary loss change factors

    50 △1 △2 - + 12 +12 +9 +6 △50 △100 △150 △200 △303 △267 △250 △300 △350 2024年3月期 2Q累計 増収要因 収益率の改善 研究開発投資 経費支出の増加 受取研究収入 株式交付費 2025年3月期 2Q累計 経常損失 経常損失 支出時期見直し 6 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  8. Slide 8: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

    200 180 160 140 120 171 100 137 80 60 116 40 72 72 74 20 0 7 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  9. Slide 9: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

    4 5 10 13 35 46 21 33 28 46 7 10 3 6 20 23 128 182 8 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  10. Slide 10: Reference literature links

     https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10931064/pdf/cancers-16-00869.pdf  https://www.redjournal.org/article/S0360-3016(24)00466-8/abstract  https://www.thegreenjournal.com/article/S0167-8140(24)00652-2/abstract  https://onlinelibrary.wiley.com/doi/10.1002/cam4.7250  https://www.scienced

  11. Slide 11: Balance sheet

    3,629 5,029 ＋1,400 (2,052) (3,552) (＋1,500) 191 175 △15 3,820 5,205 ＋1,384 455 219 △235 988 1,905 ＋917 1,443 2,125 ＋681 2,377 3,079 ＋702 3,820 5,205 ＋1,384 62.0％ 59.2％ △2.8％ 10 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  12. Slide 12: Cash flow

    △435 545 +981 △10 88 +98 308 865 +557 △138 1,499 +1,637 2,669 2,012 △657 2,531 3,511 +980 11 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  13. Slide 13: Financial details

    3,108 1,786 △1,322 217 217 (3) 632 312 (-) 513 175 (10) 703 703 (257) 145 - (53) 60 40 (-) 838 338 (-) 3,108 1,786 (323) 12 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  14. Slide 14: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

    13 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  15. Slide 15: Full-year forecast

    ・前期に比べてBNCTの認知度向上が進んできたこともあり、国内売上高は堅調に推移すると予想 ・海外売上高(中国海南島向)に関しては、予定どおり第４四半期での計上を見込む 169 761 930 269 + 661 169 161 330 269 + 61 - 600 600 - + 600 438 744 1,182 1,029 + 153 (136) (303) (439) (393) (+ 46) △ 269 17 △ 252 △ 760 + 508 △ 267 10 △ 257 △ 760 + 502 △ 268 8 △ 260 △ 763 + 503 14 COPYRIGHT Ⓒ ST

  16. Slide 16: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

    15 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  17. Slide 17: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

    16 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

  18. Slide 18: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

    COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED. 17

  19. Slide 19: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

    18 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

  20. Slide 20: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

    COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED. 19

  21. Slide 21: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

    ➀ ➁ COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED. 20

  22. Slide 22: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

    ➂ 21 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

  23. Slide 23: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

    ➂ 22 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

  24. Slide 24: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

    ➂ 23 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

  25. Slide 25: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

    ➂ 24 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

  26. Slide 26: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

    25 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

  27. Slide 27: Regional regulatory and market plans

    日本（製造販売承認取得） 欧米市場 (2026年治験開始を目指す) （EMA、FDA） 中華人民共和国（NMPA） 海南島特区:2025年治療開始予定 その他全域:海南島特区RWDを活用した NMPA承認申請を今後計画    26 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

  28. Slide 28: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

      27 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

  29. Slide 29: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

      28 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

  30. Slide 30: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

    29 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

  31. Slide 31: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

         30 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHTS RESERVED.

  32. Slide 32: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

    31 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  33. Slide 33: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

    32 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  34. Slide 34: BNCT's place in radiation therapy

    IMRT 効果の範囲は IGRT 画像診断結果に依存 陽子線 照射範囲の高精度化 重粒子線 X線, ガンマ線 ブラッグピークの利用で 表層部の被ばく量低減 BNCT 放射線 BNCTは 外科 化合物の生体分布を利用して 治療 細胞を選択的に照射 集学的治療の一翼を担う 治療 放射線治療の発展形である 免疫 その他 化学療法 治療 光免疫 先進医療等 治療 33 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  35. Slide 35: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

    34 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  36. Slide 36: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

    • • • • • • • 35 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  37. Slide 37: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

    36 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  38. Slide 38: Target operating profit in FY2027/3 of medium-term plan

    中期経営計画3年目(2027年3月期)に、営業利益の黒字化を目指す 37 COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  39. Slide 39: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

         COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

  40. Slide 40: COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

    COPYRIGHT Ⓒ STELLA PHARMA CORPORATION. ALL RIGHT RESERVED.

Stella Pharma — Q2 FY2025/3 Earnings Presentation on 6ix